Clinical Trial Update: the Prevention of Bone Marrow Suppression Caused by Chemotherapy in Advanced NSCLC With Trilaciclib [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating trilaciclib to prevent chemotherapy-induced bone marrow suppression in advanced non-small cell lung cancer. The study is …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• trilaciclib (trilaciclib)

Snippet

Sponsor: Henan Cancer Hospital | Conditions: Non-small Cell Lung Cancer | Phase 2 | Status: ENROLLING_BY_INVITATION